Snapshot from Sep 21, 2026 at 07:00 UTC. For live data and tracking: View Live
Business strategic investment

Cohance Lifesciences invests in ADC firms

Analysis based on 7 articles · First reported Sep 03, 2026 · Last updated Sep 04, 2026

Sentiment
15
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The investment signals Cohance's strategic expansion into the ADC market, potentially enhancing its growth prospects and attracting investor interest. The transactions are expected to strengthen Cohance's integrated CRDMO capabilities and control over Aruka's proprietary ADC platform, which may positively impact its valuation and market position.

Pharmaceuticals Biotechnology Contract Research and Manufacturing

Eris Lifesciences, formerly Suven Pharmaceuticals, announced an $18 million investment to strengthen its antibody-drug conjugate (ADC) strategy. The company will invest $13 million in NJ Bio, increasing its ownership from 56% to 67.3%, and $5 million in Aruka Bio, acquiring a 65% controlling stake. The transactions, funded through internal accruals, aim to integrate NJ Bio's customer-facing contract research and manufacturing services with Cohance's manufacturing capabilities, while Aruka Bio will focus on developing next-generation ADCs. The restructuring follows a review of NJ Bio's performance since December 2024. Completion is expected by the end of September 2026, subject to definitive agreements and customary conditions. Dr. Naresh Pal will continue to lead NJ Bio and eventually move full-time to Aruka as CEO.

80 Eris Lifesciences announced investment
70 Eris Lifesciences acquired holdings Priyashri Nayak
70 Eris Lifesciences acquired holdings Jain Family Irrevocable Trust
stock
Cohance is the investor and parent company, increasing stakes in NJ Bio and Aruka Bio to strengthen its ADC strategy. The investment is expected to enhance its integrated capabilities and market position.
Importance 100.0 Sentiment 20.0
priv
NJ Bio receives $13 million investment, increasing Cohance's ownership to 67.3%. It will remain focused on contract research and manufacturing, with closer integration into Cohance's operations.
Importance 80.0 Sentiment 15.0
priv
Aruka Bio receives $5 million investment, giving Cohance a 65% controlling stake. The funding will support buyout of existing shareholders and working capital, positioning it for partnerships.
Importance 80.0 Sentiment 20.0
per
Dr. Jain retains stakes in NJ Bio and Aruka Bio, continues to lead NJ Bio, and will eventually become CEO of Aruka. His leadership is central to the reorganization.
Importance 60.0 Sentiment 10.0
per
Umang Vohra, executive chairman and group CEO of Cohance, commented on the reorganization, highlighting the clear focus for each business.
Importance 30.0 Sentiment 5.0
per
Priyashri Nayak's entire holdings in NJ Bio are acquired by Cohance as part of the transaction.
Importance 20.0 Sentiment 0.0
oth
The trust's entire holdings in NJ Bio are acquired by Cohance as part of the transaction.
Importance 20.0 Sentiment 0.0
exch
The NSE is the exchange where Cohance's shares are listed; the announcement was filed with the NSE.
Importance 10.0 Sentiment 0.0
curr
The investment amounts are denominated in US dollars, reflecting the cross-border nature of the transactions.
Importance 10.0 Sentiment 0.0
curr
Cohance's share price is quoted in India — Indian rupees on the NSE, closing at ₹459.05 on September 3.
Importance 5.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.